March 3, i. Medication Reconciliation Post Discharge (Part C) (p. 79)
|
|
- Cornelia Randall
- 6 years ago
- Views:
Transcription
1 March 3, 2017 [Submitted electronically to Centers for Medicare & Medicaid Services U.S. Dept. of Health & Human Services Attention: CMS-4159-P P.O. Box 8013 Baltimore, MD Re: Advance Notice of Methodological Changes for Calendar Year (CY) 2018 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2018 Call Letter Dear Sir/Madam: The American Pharmacists Association (APhA) is pleased to submit our comments on the Centers for Medicare & Medicaid Services (CMS) Advance Notice of Methodological Changes for Calendar Year (CY) 2018 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2018 Call Letter (the Call Letter ). Founded in 1852 as the American Pharmaceutical Association, APhA represents 64,000 pharmacists, pharmaceutical scientists, student pharmacists, pharmacy technicians, and others interested in improving medication use and advancing patient care. APhA members provide care in all practice settings, including community pharmacies, hospitals, long-term care facilities, community health centers, physician offices, ambulatory clinics, managed care organizations, hospice settings, and the uniformed services. I. Star Ratings and Display Measures APhA s members are committed to continuous quality improvement and support the development and use of meaningful measures that help patients achieve optimal health and medication outcomes. APhA thanks CMS for the opportunity to offer our comments regarding enhancements to the Star Ratings and display measures in CY A. New Star Ratings measures i. Medication Reconciliation Post Discharge (Part C) (p. 79) APhA supports the addition of this measure to help determine MA-PD s star ratings and looks forward to working with CMS to add it to a broader set of future measures related to care transitions. Inclusion of the medication reconciliation postdischarge measure in the MA-PD star ratings program is consistent with measures used in other CMS programs such as the ACO measures in the Medicare Shared Savings
2 APhA Comments to CMS re: CY 2018 Call Letter Page 2 of 7 Program (MSSP) and the quality measures in the Merit-based Incentive Payment System (MIPS) within the Quality Payment Program (QPP). 1 APhA and its members are very grateful for CMS s continued recognition of the value of pharmacists and implementation of policies that promote pharmacists involvement in patient care, including the Medication Reconciliation Post Discharge measure that references pharmacists. In addition to recognizing the strong role that pharmacists can play in the postdischarge care of beneficiaries, APhA strongly urges CMS to implement policies which facilitate pharmacists involvement in a patient s care coordination process other than at discharge. Better, as well as earlier, incorporation of pharmacists and their medication expertise in patient care is consistent with the movement to coordinated care 2,3 and other team-based care models to more effectively maximize the members of the health care team and benefit patients. B. Removal of Star Ratings measures i. High Risk Medications in the Elderly measure (Part D) (pgs. 82, ) APhA agrees with CMS s proposal, based upon statements from the Pharmacy Quality Alliance (PQA) and the American Geriatrics Society, to move the High Risk Medications in the Elderly (HRM) measure from a Star Ratings measure to a display measure in We appreciate the change is due to concerns that the measure should not be punitive as medications on the HRM list are not contraindications and are only recommendations and considerations. 4 C CMS display measures While not included in the plan ratings, CMS and plans use display measures, to facilitate quality improvement. All previous 2017 display measures will continue as display measures for However, some of the measures contain specification changes, and there are new measures proposed. In general, APhA supports the following display measures highlighted below that relate to pharmacists and pharmacist services. APhA would also support moving these measures from display measures to Star Ratings measures in the future if experience and assessment merit their inclusion. i. Pneumococcal Vaccination Status for Older Adults (Part C) (pgs ) APhA supports CMS s efforts to explore better ways (e.g., claims, case management systems, medical records, registries and electronic health records) to assess pneumococcal vaccination status, other than through CAHPS survey data. Relying upon 1 See, CMS. Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2017, Final Rule. 81 FR Pg November 15, Available at: 2 See, The Patient-Centered Primary Care Collaborative. Integrating Comprehensive Medication Management to Optimize patient Outcomes. June Available at: 3 See, American College of Physicians (ACP) Practice Advisor. Collaborative Medication Management. Module Available at: 4 CMS. Announcement of Calendar Year (CY) 2017 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter. Pgs April 4, Available at: Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2017.pdf 2
3 APhA Comments to CMS re: CY 2018 Call Letter Page 3 of 7 patient recall and understanding regarding which pneumococcal vaccine(s), if any, a patient might have received is an unreliable method to determine immunization status. Encouraging all immunization providers to report vaccines administered to patients will provide a comprehensive database from which to measure patient immunization status. ii. Statin Therapy for Patients with Cardiovascular Disease (Part C) (p. 98) APhA is unclear what is meant by CMS s statements, [s]ince the HEDIS statin measures overlap with the measures developed by the PQA, CMS included only one of the HEDIS measures on the 2017 display page and will retain it on the 2018 display page. After gaining experience with the new treatment guidelines and metric, we plan to include this measure in the 2019 Star Ratings. We ask for clarity which HEDIS measure(s) overlaps with which PQA measure(s) and also verification that CMS plans to use the HEDIS statin measure in the Part C Star Rating program and the PQA Statin measure (Statin Therapy in Persons with Diabetes) in the Part D Star Ratings program. iii. Drug-Drug Interactions (Part D) (pgs ) APhA continues to support this measure as CMS is planning to implement the revised measure drug list, which PQA updated, for the 2019 display measures using 2017 data. iv. Antipsychotic Use in Persons with Dementia (APD) (Part D) (p. 101) Generally, APhA supports measuring the percentage of Medicare Part D beneficiaries 65 years or older with dementia who received prescription fills for antipsychotics without evidence of a psychotic disorder or related condition. As CMS is aware, pharmacists have extensive medication-related experience and training, and can assist in helping treat seniors with dementia. Pharmacists can also help address a number of concerns for care transitions for patients with dementia (i.e., medication reconciliation, comprehensive medication reviews, etc.). 5 Therefore, we reiterate our call to CMS to implement measures and policies that encourage team-based care, and effectively optimize pharmacists and other practitioners skills to improve patient care. v. Use of Opioids from Multiple Providers (OHDMP) and/or at High Dosage (OHD) in Persons without Cancer (Part D) (pgs ) APhA supports addressing and improving opioid prescribing and management, while recognizing the need for patients to have access to safer, more effective chronic pain treatment 6 and remembering the millions of patients with chronic pain in need of legitimate access to appropriate prescription pain medications. APhA supports CMS s proposal to implement the PQA s recently-approved changes to these measures. 7 We also 5 Burke, Robert. Et. al. Dementia in Care Transitions. The Society for Post-Acute and Long-Term Care Medicine. White Paper M16. Introduced in March Available at: %20TOC%20Dementia%20White%20Paper.pdf 6 CMS. Announcement of Calendar Year (CY) 2017 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter. Pg April 4, Available at: Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2017.pdf 7 Changes include: The treatment period for OHD and opioids at high doses from multiple providers must be 90 days or more. MED is changed to morphine milligram equivalents. ICD-9, 10 codes will be changed to align with the American Medical Association Physician Consortium for Performance Improvement cancer value set. All buprenorphine products indicated for medication-assisted treatment (MAT) will be excluded. 3
4 APhA Comments to CMS re: CY 2018 Call Letter Page 4 of 7 support efforts continuing to refine these measures using the best available scientific evidence. Accordingly, APhA supports CMS s proposal to not add these measures to Star Ratings at this time. vi. Statin Use in Persons with Diabetes (Part D) (pgs ) APhA supports this PQA-endorsed measure of patients between years old who received at least two diabetes medication fills and received a statin medication during the measurement period (excluding ESRD and hospice patients). We also support this measure becoming a Star Ratings measure for 2019 as it will facilitate increased management of statin therapy in persons with diabetes. D. Measures for 2019 and beyond i. Telehealth and Remote Access Technologies (p. 104) APhA appreciates that CMS welcomes feedback on the appropriateness of including telehealth and/or remote access technology encounters (including behavioral health) as allowed under the current statutory definition of Medicare covered telehealth services and/or as provided by an MA plan as a supplemental benefit, as eligible encounters in various future Part C quality measures. As CMS understands, Medication Therapy Management (MTM) under Part D can be delivered in a telehealth format. Therefore, as CMS facilitates its telehealth delivery criteria, APhA urges CMS to continue to improve the exchange of clinical information between health care practitioners in all its policies or programs, including pharmacists. Pharmacists regularly provide services to improve safe and appropriate medication use; adherence for the elderly and other populations; medication reconciliation; wellness and prevention; chronic disease management programs; and case management for beneficiaries with multiple medications that require complex medication dosing regimens. However, pharmacists are frequently blocked from the electronic exchange of relevant clinical information, which is critical to maximize the benefit of coordinated team-based care. Therefore, we also encourage CMS s continued help in facilitating the electronic exchange of clinical information between pharmacists and other health care providers to improve the delivery of coordinated, team-based care and benefit patients. ii. Care Coordination (Part C) (pgs ) APhA thanks CMS for its efforts to identify meaningful care coordination measures and supports its efforts to consider them as an immediate outcome measure. As CMS and its contractors 8 consider the activities that best represent care coordination measures for MA and MA-PD plans, starting with the 2019 star ratings, APhA requests that CMS consider examining the contributions of pharmacists to appropriate care coordination, especially as it relates to optimizing medication therapies. Medication-related problems often occur due to lack of care coordination, and pharmacists can play an important role in managing medications across multiple providers, including communicating medication 8 Impaq International. CMS Awards IMPAQ Contract to Support Quantifiable Care Coordination Measures for Medicare Advantage Plans. November 10, Available at: 4
5 APhA Comments to CMS re: CY 2018 Call Letter Page 5 of 7 information and exchanging reconciled medication lists. Therefore, APhA recommends that as CMS explores new care coordination measures, measured activities include the contributions of pharmacists. iii. Transitions of Care (Part C) (pgs ) APhA is pleased that CMS understands the vital role that pharmacists can play in ensuring safe transitions of care. APhA appreciates that Medication Reconciliation is included as one of the 4 indicators under the new Transitions of Care measure. In addition to the Medication Reconciliation indicator for this measure, CMS should consider pharmacists roles in the Notification of Inpatient Admission, Receipt of Discharge Information, and Patient Engagement after Discharge indicators. As the first health care practitioner patients often encounter post-discharge, pharmacists could benefit greatly from better inclusion in the sharing of pertinent clinical information and often are the health care practitioner coordinating medication-related information between the hospital and primary care physician. Pharmacists/pharmacies can act as access points for sharing of medication information vital to appropriate medication reconciliation during any care transition a patient experiences to improve care and reduce costs. For example, connectivity of the community pharmacist with the hospital pharmacist and primary care physicians under the Hawaii CMS Innovation Center (CMMI) project reduced the medication-related hospitalization rate of individuals aged 65 and older by 36.5% than in nonintervention hospitals with an estimated $6.6 million in annual avoided admissions. 9 Therefore, APhA requests that CMS consider the role of pharmacists when developing the indicators for this new Transitions of Care measure. iv. CMS Expectation for Hard Formulary-Level Cumulative Opioid MED POS Safety Edits in CY 2018 (pgs ) APhA has long been strongly supportive of programs that effectively target and deter prescription drug abuse and misuse. APhA supports CMS s efforts to help address this epidemic, provided its policies are scientifically- based and carefully structured to ensure that patients with a legitimate need have access to medications. APhA appreciates CMS s proposal to require point-of-sale (POS) edits based on the cumulative morphine equivalent dose (MED). APhA understands the difficulty in setting an MED upper limit for a hard edit. Our members tell us that the majority of beneficiaries that reach 200 mg likely have a combination of short and long acting pain medications and have had to choose whether to fill them to avoid hitting the limit. Imposing hard edits can result, in some cases, plans rejecting, at least temporarily, the medically necessary prescriptions of beneficiaries with legitimate needs. Adding to the complexity, many patients whose legitimate medical needs requires opioids at an upper limit that may trigger a hard edit, and receive prescriptions that indicate the date that they are allowed to fill it written on the script itself a date that is chosen because it is the day they will run out of their medication. Often a hard edit, or the time necessary to receive prior authorization may exceed the prescription date forcing patients to unnecessarily return to see their physicians. APhA 9 Pellegrin, Karen. Et. al. Reductions in Medication-Related Hospitalizations in Older Adults with Medication Management by Hospital and Community Pharmacists: A Quasi-Experimental Study. Journal of the American Geriatrics Society. October 7, Available at: 5
6 APhA Comments to CMS re: CY 2018 Call Letter Page 6 of 7 appreciates CMS s acknowledgement that plans should account for high-dose opioid usage previously determined to be medically necessary such as through case management or the coverage determination and appeals process. We strongly recommend that plans establish a process, prior to implementing hard edits, to proactively address the appropriate authorization for patients who are receiving high doses of opioids for legitimate needs, particularly those patients who are currently receiving these medications long-term. In addition, prescribers often switch medications instead of completing prior authorizations for POS edits thinking that will take care of the issue, which, again, is causing patients to make trips back and forth to the doctor's office, which may cover significant distances. APhA members have informed us that patients often come back with another prescription and pharmacists encounter the exact same problem. APhA members believe the POS edits need to be a clearly defined, in a consistently applied process that will allow overrides, if appropriate, to be completed on the same day given the fact that the prescriptions are written only allowing the fill process to occur on the very last day that patients will run out of medication(s). In addition, setting hard stops may lead to an increase in the volume of patients seeking relief through illegal methods. As the plans implement POS edits, APhA encourages both the plans and CMS to engage with pharmacists and prescribers to craft evidence-based POS edits that can proactively prevent overutilization without compromising patient access to medically-necessary opioids. To assist these efforts, CMS and the plans should support the policy adopted by APhA s House of Delegates (HOD) for automation and technology in pharmacy practice that supports nationwide integration of prescription drug monitoring programs (PDMP) that incorporate federal, state, and territory databases for the purpose of providing health care professionals with accurate and real-time information to assist in clinical decision making when providing patient care services related to controlled substances. 10 II. Part D Requirements A. Medication Therapy Management (MTM): Annual MTM Eligibility Cost Threshold (pgs , ) APhA appreciates CMS s continued support for MTM programs, which improve medication-related and overall health outcomes. Studies indicate that for every $1 spent on MTM services, anywhere from $4 up to $12 is saved in addition to cost savings, patients also realize significant improvements in key health measures. 11 Despite clear evidence supporting the value of pharmacist-led MTM services, these programs continue to be significantly underutilized. As APhA has previously stated, we strongly encourage CMS to revisit the cost threshold, as the current $3,919 threshold, which increased $412 from the previous year, excludes many beneficiaries with complex conditions, but smaller drug spends, potentially through the use of generic medications, who could benefit from MTM services. This point is reinforced by the fact that the United States spends $300 billion annually on medication-related problems. 12 While APhA appreciates CMS s ongoing efforts 10 APhA. HOD. Current Adopted Policy Statements Integrated Nationwide Prescription Drug Monitoring Program. Pg Available at: 11 Isetts, BJ. Et. al. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc. 2008; 48(2): Available at: 12 NEHI. Thinking Outside the Pillbox: A System-wide Approach to Improving Patient Adherence for Chronic Disease. August Available at: 6
7 APhA Comments to CMS re: CY 2018 Call Letter Page 7 of 7 to expand and enhance MTM, including the Enhanced MTM Model test, we hope that CMS will continue to work collaboratively with pharmacists, plans, and beneficiaries to improve and streamline MTM eligibility criteria (including the number of medications and chronic conditions) in order to maximize the services benefits to both patients and the larger health care system. B. Access to Preferred Cost-Sharing Pharmacies (PSCP) (pgs ) APhA, like CMS, advocates for increasing patient access to affordable medications. APhA was pleased to see, through CMS s efforts to increase transparency within the Medicare program, the reported increases in PSCP access for urban, rural, and suburban beneficiaries for 2018 and the requirement for outlier plans to disclose in marketing materials, including websites, that their plans may offer lower access to PSCP networks. However, APhA remains concerned that while current plan networks include PCSPs, beneficiaries may still encounter logistical hurdles in actually accessing PSCPs. APhA believes that if CMS offers additional pharmacies the opportunity to participate in Part D plans, patients will have increased access to benefits and services, which may result in improved outcomes from their medications. Thus, APhA continues to advocate for a requirement that Part D plans contract with any pharmacy willing to accept their contractual terms and conditions. Thank you for the opportunity to provide comments on the draft Call Letter. We support CMS s ongoing efforts to continue to improve Medicare s prescription drug programs and look forward to continuing to work with CMS to reach that goal. If you have any questions or require additional information, please contact Michael Baxter, Director of Regulatory Affairs, at mbaxter@aphanet.org or by phone at (202) Sincerely, Thomas E. Menighan, BSPharm, MBA, ScD (Hon), FAPhA Executive Vice President and CEO cc: Stacie S. Maass, RPh, JD, Senior Vice President, Pharmacy Practice and Government Affairs, APhA The Honorable Tom Price, M.D., Secretary, U.S. Department of Health and Human Services 7
i. CMS/RAND-convened Technical Expert Panel (TEP) in 2018 (p. 106)
March 5, 2018 [Submitted electronically to www.regulations.gov] The Honorable Seema Verma Centers for Medicare & Medicaid Services U.S. Department of Health & Human Services (CMS) P.O. Box 8013 Baltimore,
Draft 2014 CMS Advanced Notice and Call Letter to Medicare Advantage and Part D Prescription Drug Plans
Jonathan Blum Center for Medicare Center for Medicare and Medicaid Services Hubert H. Humphrey Building 200 Independence Avenue, SW, MS:314G Washington, DC 20201 [Submitted electronically to: AdvanceNotice2014@cms.hhs.gov]
Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2013 [File Code CMS 1590 P]
Centers for Medicare & Medicaid Services Attention: CMS 1590 P Mail Stop C4 26 05 7500 Security Boulevard Baltimore, MD 21244 1850 [Submitted online at: http://www.regulations.gov] Re: Medicare Program;
December 12, [Submitted online at:
Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMS-4157-P Room C4-26-05 7500 Security Boulevard Baltimore, MD 21244-1850 [Submitted online at: www.regulations.gov]
Pharmacy Quality Measures: What They Are and How Community Pharmacies Can Impact Them in Their Practice
Pharmacy Quality Measures: What They Are and How Community Pharmacies Can Impact Them in Their Practice Zac Renfro, PharmD, Pharmacy Quality Consultant Pharmacy Quality Solutions Disclosure and Conflict
Pharmacy Quality Measures. Presentation Developed for the Academy of Managed Care Pharmacy Updated: February 2013
Pharmacy Quality Measures Presentation Developed for the Academy of Managed Care Pharmacy Updated: February 2013 Objectives Explain the purpose of quality measures and how they are developed Identify quality
I. Coordinating Quality Strategies Across Managed Care Plans
Jennifer Kent Director California Department of Health Care Services 1501 Capitol Avenue Sacramento, CA 95814 SUBJECT: California Department of Health Care Services Medi-Cal Managed Care Quality Strategy
MEDICARE PART D STAR RATINGS & PHARMACY PERFORMANCE
MEDICARE PART D STAR RATINGS & PHARMACY PERFORMANCE LISA R. ERWIN, R.PH., CGP SENIOR CONSULTANT AUGUST 21, 2015 WHO IS GORMAN HEALTH GROUP? Gorman Health Group is the leading solutions and consulting firm
Evaluation & Management ( E/M ) Payment and Documentation Requirements
National Partnership for Hospice Innovation 1299 Pennsylvania Ave., Suite 1175 Washington DC, 20004 September 10, 2017 Seema Verma Administrator Centers for Medicare & Medicaid Services, Department of
RE: CMS-1677-P; Medicare Program; Request for Information on CMS Flexibilities and Efficiencies
June 13, 2017 Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMS-1677-P P.O. Box 8011 Baltimore, MD 21244-1850 RE: CMS-1677-P;
Getting Ready for the Maryland Primary Care Program
Getting Ready for the Maryland Primary Care Program Presentation to Maryland Academy of Nutrition and Dietetics March 19, 2018 Maryland Department of Health All-Payer Model: Performance to Date Performance
March 5, March 6, 2014
William Lamb, President Richard Gelula, Executive Director March 5, 2012 Ph: 202.332.2275 Fax: 866.230.9789 www.theconsumervoice.org March 6, 2014 Marilyn B. Tavenner Administrator Centers for Medicare
Leading By Example. Begin with a vision. Disclosures. Learning Objectives 3/25/2017. Tripp Logan, PharmD
Leading By Example Melissa Somma McGivney, PharmD, FAPhA, FCCP Associate Dean for Community Partnerships; Associate Professor University of Pittsburgh Tripp Logan, PharmD Senior Quality Consultant - MedHere
1500 West Park Drive Suite 100 Westborough, MA (508) August 21, 2018
1500 West Park Drive Suite 100 Westborough, MA 01581 (508) 621-7320 August 21, 2018 Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Subject: CMS-1693-P Dear Madam/Sir,
HEDIS Updates to quality ratings, measures & reporting. Wilhelmina Delostrinos, Director of Quality Improvement & Accreditation
HEDIS 2018 Updates to quality ratings, measures & reporting Wilhelmina Delostrinos, Director of Quality Improvement & Accreditation Agenda HEDIS Overview HEDIS 2018 Changes to Existing Measures HEDIS 2018
Benefits of National Provider Identifier
Florida Pharmacy Association Professional Affairs Council Benefits of National Provider Identifier Written by: Kayla Mackanin, USF PharmD Candidate 2015, Professional Affairs Council Member Created on:
VIA Electronic Submission to
VIA Electronic Submission to http://www.regulations.gov/#!documentdetail;d=cms-2012-0145-0001 December 27, 2012 Centers for Medicare & Medicaid Services Department of Health and Human Services Attention:
Prior to implementation of the episode groups for use in resource measurement under MACRA, CMS should:
Via Electronic Submission (www.regulations.gov) March 1, 2016 Andrew M. Slavitt Acting Administrator Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD episodegroups@cms.hhs.gov
Pharmacy Pain Management Protocol Pharmacy Policy and Protocol
Line of Business: Medicare and Medi-Cal Effective Date: November 18, 2015 Renewal Date: August 16, 2017 Pharmacy Pain Management Protocol Pharmacy Policy and Protocol This protocol has been developed through
Medicare Advantage Star Ratings
Medicare Advantage Star Ratings December 2017 The Star Rating System measures how well Medicare Advantage (MA) and its prescription drug plans perform for consumers. As an integrated health system, Presbyterian
CMS Quality Payment Program: Performance and Reporting Requirements
CMS Quality Payment Program: Performance and Reporting Requirements Session #QU1, February 19, 2017 Kristine Martin Anderson, Executive Vice President, Booz Allen Hamilton Colleen Bruce, Lead Associate,
Promoting Interoperability Performance Category Fact Sheet
Promoting Interoperability Fact Sheet Health Services Advisory Group (HSAG) provides this eight-page fact sheet to help providers with understanding Activities that are eligible for the Promoting Interoperability
Expanding Your Pharmacist Team
CALIFORNIA QUALITY COLLABORATIVE CHANGE PACKAGE Expanding Your Pharmacist Team Improving Medication Adherence and Beyond August 2017 TABLE OF CONTENTS Introduction and Purpose 1 The CQC Approach to Addressing
Promoting Interoperability Measures
Promoting Interoperability Measures Previously known as Advancing Care Information for 2017 and Meaningful Use from 2011-2016 Participants: In 2018, promoting interoperability measure reporting (PI) is
Insights into Pharmacist Provided MTM Services-Present and Future
Insights into Pharmacist Provided MTM Services-Present and Future Anne Burns, RPh Vice President, Professional Affairs American Pharmacists Association Learning Objectives Describe the scope of MTM service
Our comments focus on the following components of the proposed rule: - Site Neutral Payments,
Mr. Andy Slavitt Acting Administrator Centers for Medicare & Medicaid Services Department of Health & Human Services Hubert H. Humphrey Building 200 Independence Ave., S.W. Room 445-G Washington, DC 20201
Goals & Challenges for Outpatient Quality Directors. Quality HealthCare Consulting, LLC CEO: Jennifer O'Donnell, MHA, PCMH-CCE
Goals & Challenges for Outpatient Quality Directors Quality HealthCare Consulting, LLC CEO: Jennifer O'Donnell, MHA, PCMH-CCE Objectives Learn a practical way for Quality Directors to align Quality Measures
Re: 42 CFR Part 485; Medicare Program; Conditions of Participation (CoPs) for Community Mental Health Centers
August 12, 2011 Centers for Medicare & Medicaid Services Department of Health and Human Services P.O. Box 8013 Baltimore, MD 21244-8013 Re: 42 CFR Part 485; Medicare Program; Conditions of Participation
Quality Measures and Federal Policy: Increasingly Important and A Work in Progress. American Health Quality Association Policy Forum Washington, D.C.
Quality Measures and Federal Policy: Increasingly Important and A Work in Progress American Health Quality Association Policy Forum Washington, D.C. February 9, 2016 Quality Journey NCQA Develops Health
WELCOME. Kate Gainer, PharmD Executive Vice President and CEO Iowa Pharmacy Association
WHAT IS MACRA? WELCOME Kate Gainer, PharmD Executive Vice President and CEO Iowa Pharmacy Association WELCOME Anthony Pudlo, PharmD, MBA, BCACP Vice President of Professional Affairs Iowa Pharmacy Association
The Influence of Health Policy on Clinical Practice. Dr. Kim Kuebler, DNP, APRN, ANP-BC Multiple Chronic Conditions Resource Center
The Influence of Health Policy on Clinical Practice Dr. Kim Kuebler, DNP, APRN, ANP-BC Multiple Chronic Conditions Resource Center Disclaimer Director: Multiple Chronic Conditions Resource Center www.multiplechronicconditions.org
Re: Centers for Medicare & Medicaid Services: Innovation Center New Direction
Via Email to: CMMI_NewDirection@cms.hhs.gov November 20, 2017 Amy Bassano, Acting Director Center for Medicare and Medicaid Innovation Centers for Medicare and Medicaid Services United States Department
Rodney M. Wiseman, DO, FACOFP dist. ACOFP President
November 20, 2017 VIA ELECTRONIC SUBMISSION (CMMI_NewDirection@cms.hhs.gov) Seema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMMI Request
Keenan Pharmacy Care Management (KPCM)
Keenan Pharmacy Care Management (KPCM) This program is an exclusive to KPS clients as an additional layer of pharmacy benefit management by engaging physicians and members directly to ensure that the best
MACRA Frequently Asked Questions
Following the release of the Quality Payment Program Interim Final Rule, the American Medical Association (AMA) conducted numerous informational and training sessions for physicians and medical societies.
Division C: Increasing Choice, Access, and Quality in Health Care for Americans TITLE XV: Provisions Relating to Medicare Part A
Division C: Increasing Choice, Access, and Quality in Health Care for Americans TITLE XV: Provisions Relating to Medicare Part A Sec. 15001. Development of Medicare study for HCPCS versions of MS-DRG codes
POLICY AND PROCEDURE DEPARTMENT: Pharmacy Operations
PAGE: 1 of 6 SCOPE: Centene Corporate Pharmacy Department, Centene Corporate Pharmacy and Therapeutics Committee, Health Plan Pharmacy Departments, Health Plan Pharmacy and Therapeutics Committees, and
Advancing Care Information Performance Category Fact Sheet
Fact Sheet The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) replaced three quality programs (the Medicare Electronic Health Record (EHR) Incentive program, the Physician Quality Reporting
Ambulatory Care Practice Trends and Opportunities in Pharmacy
Ambulatory Care Practice Trends and Opportunities in Pharmacy David Chen, R.Ph., M.B.A. Senior Director Section of Pharmacy Practice Managers ASHP Objectives Describe trends in health system pharmacy reported
2019 Quality Improvement Program Description Overview
2019 Quality Improvement Program Description Overview Introduction Eon/Clear Spring s Quality Improvement (QI) program guides the company s activities to improve care and treatment for the member s we
T O G E T H E R W E M A K E A G R E A T T E A M. January 6, 2014
7272 Wisconsin Avenue Bethesda, Maryland 20814 301-657-3000 Fax: 301-664-8877 www.ashp.org Richard Kronick, Ph.D. Director, Agency for Healthcare Research and Quality Agency for Healthcare Research and
Quality Management Report 2018 Q1
Quality Management Report 2018 Q1 Care Wisconsin Participates in Many Quality Initiatives Across the State and Federal Levels These activities include: Centers for Medicare & Medicaid Services (CMS) Department
Advancing Care Information Measures
Participants: Advancing Care Information Measures In 2017, Advancing Care Information (ACI) measure reporting is optional for Nurse Practitioners, Physician Assistants, Clinical Nurse Specialists, CRNAs,
2017 House of Delegates Report of the Policy Committee
2017 House of Delegates Report of the Policy Committee Patient Access to Pharmacist-Prescribed Medications Pharmacists Role within Value-Based Payment Models Pharmacy Performance Networks Committee Members
Medicaid Efficiency and Cost-Containment Strategies
Medicaid Efficiency and Cost-Containment Strategies Medicaid provides comprehensive health services to approximately 2 million Ohioans, including low-income children and their parents, as well as frail
Quality Management Report 2017 Q4
Quality Management Report 2017 Q4 Care Wisconsin Participates in Many Quality Initiatives Across the State and Federal Levels. These activities include: CMS DHS DHS & CMS HEDIS Member Satisfaction (CAHPS
Passport Advantage Provider Manual Section 8.0 Quality Improvement
Passport Advantage Provider Manual Section 8.0 Quality Improvement Table of Contents 8.1 Quality Improvement Program 8.2 Clinical Practice Guidelines 8.3 Star s 8.4 Quality of Care Concerns 8.3 Practitioner
Disclosures. Learning Objectives 4/26/2017. Impact of a Pilot Ambulatory Care Pharmacist in a Family Practice Clinic
Impact of a Pilot Ambulatory Care Pharmacist in a Family Practice Clinic Taylor Sandvick, PharmD, PGY1 Pharmacy Resident St. Peter s Hospital, Helena, MT April 29, 2017 Disclosures 2 Financial: Nothing
Primary goal of Administration Patients Over Paperwork
Meaningful Measures Presented by: Maria Durham, Director, Kevin Larsen, MD, Director Continuous Improvement and Strategic Planning, Centers for Medicare & Medicaid Services Discussion Topics Introduction
Highlights of the 2018 Medicare Physician Fee Schedule (MPFS) Final Rule
Highlights of the 2018 Medicare Physician Fee Schedule (MPFS) Final Rule Physician Payment Update & Misvalued Codes Target The update to payments under the PFS in 2018 will be +0.31 percent. This reflects
March Data Jam: Using Data to Prepare for the MACRA Quality Payment Program
March Data Jam: Using Data to Prepare for the MACRA Quality Payment Program Elizabeth Arend, MPH Quality Improvement Advisor National Council for Behavioral Health CMS Change Package: Primary and Secondary
PBM SOLUTIONS FOR PATIENTS AND PAYERS
PBM SOLUTIONS FOR PATIENTS AND PAYERS Reducing Prescription Drug Costs Designing Solutions for Employers, Unions, and Government Programs Delivering High Patient Satisfaction and Improved Outcomes Improving
Submitted electronically:
Mr. Andy Slavitt Acting Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMS-5517-FC P.O. Box 8013 7500 Security Boulevard Baltimore, MD 21244-8013
Executive, Legislative & Regulatory 2018 AGENDA. unitypoint.org/govaffairs
Executive, Legislative & Regulatory 2018 AGENDA unitypoint.org/govaffairs Dear Policy Makers and Community Stakeholders, In the midst of tumultuous times, we bring you our 2018 State Legislative Agenda.
UPDATE ON MEANINGFUL USE. HITECH Stimulus Act of 2009: CSC Point of View
HITECH Stimulus Act of 2009: CSC Point of View UPDATE ON MEANINGFUL USE Introduction The HITECH provisions of the American Recovery and Reinvestment Act of 2009 provide a commanding $36 billion dollars
The New Frontier: Value- Based Payment Models
The New Frontier: Value- Based Payment Models Target Audience: Pharmacists and Pharmacy Technicians ACPE#: 0202-0000-18-026-L04-P/T Activity Type: Knowledge-based Target Audience: ACPE#: Activity Type:
Russell B Leftwich, MD
Russell B Leftwich, MD Chief Medical Informatics Officer Office of ehealth Initiatives, State of Tennessee 1 Eligible providers and hospitals can receive incentives for meaningful use of certified EHR
REPORT OF THE BOARD OF TRUSTEES
REPORT OF THE BOARD OF TRUSTEES B of T Report 21-A-17 Subject: Presented by: Risk Adjustment Refinement in Accountable Care Organization (ACO) Settings and Medicare Shared Savings Programs (MSSP) Patrice
Emerging Opportunities: Pharmacy Care. NACDS Total Store Expo August 20, 2017
Emerging Opportunities: Pharmacy Care NACDS Total Store Expo August 20, 2017 Presentation Objectives Current value based healthcare landscape Medication management as a critical component to achieve value
January 4, Dear Sir/Madam:
January 4, 2016 U.S. Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMS-3317-P P.O. Box 8016 Baltimore, MD 21244-8016 Dear Sir/Madam: The Home Care Association
ENHANCING PRESCRIBER RELATIONSHIPS: MAKING IT A WIN-WIN JULY 12, :00 5:00 PM
ENHANCING PRESCRIBER RELATIONSHIPS: MAKING IT A WIN-WIN JULY 12, 2017 3:00 5:00 PM ACPE UAN: 0107-9999-17-105-L04-P 0.2 CEU/2.0 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacists: Upon
MTM Performance & Impact On Star Ratings 2016 & Beyond - OutcomesMTM Overview
MTM Performance & Impact On Star Ratings 2016 & Beyond - OutcomesMTM Overview Today s Speaker Dan Rodriguez, RPh, BPharm Sr. Associate Network Performance OutcomesMTM Learning Objectives - Define Medication
Statement of Ronna B. Hauser, Pharm.D. Vice President, Policy and Regulatory Affairs National Community Pharmacists Association
Statement of Ronna B. Hauser, Pharm.D. Vice President, Policy and Regulatory Affairs National Community Pharmacists Association Food and Drug Administration [Docket Nos. FDA 2010 N 0284 and FDA 2009 D
TABLE H: Finalized Improvement Activities Inventory
TABLE H: Finalized Improvement Activities Inventory [We invited comments on the reassignment of improvement activities under alternate subcategories, and on the scoring weights assigned to improvement
CPC+ CHANGE PACKAGE January 2017
CPC+ CHANGE PACKAGE January 2017 Table of Contents CPC+ DRIVER DIAGRAM... 3 CPC+ CHANGE PACKAGE... 4 DRIVER 1: Five Comprehensive Primary Care Functions... 4 FUNCTION 1: Access and Continuity... 4 FUNCTION
Statement Of. The National Association of Chain Drug Stores. For. U.S. House of Representatives Committee on Ways and Means Subcommittee on Health
Statement Of The National Association of Chain Drug Stores For U.S. House of Representatives Committee on Ways and Means Subcommittee on Health Hearing on: The President s and Other Bipartisan Proposals
(b) Is administered via a transdermal route; or
ACTION: To Be Refiled DATE: 10/10/2018 2:31 PM 4723-9-10 Formulary; standards of prescribing for advanced practice registered nurses designated as clinical nurse specialists, certified nurse-midwives,
P C R C. Physician Clinical Registry Coalition. January 1, [Submitted online at: https://www.regulations.gov/document?d=cms ]
Ms. Seema Verma, MPH Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-5522-FC P.O. Box 8016 Baltimore, MD 21244-8016 P C R C Physician Clinical
Guidance for Developing Payment Models for COMPASS Collaborative Care Management for Depression and Diabetes and/or Cardiovascular Disease
Guidance for Developing Payment Models for COMPASS Collaborative Care Management for Depression and Diabetes and/or Cardiovascular Disease Introduction Within the COMPASS (Care Of Mental, Physical, And
CMS-3310-P & CMS-3311-FC,
Andrew M. Slavitt Acting Administrator Centers for Medicare & Medicaid Services Hubert H. Humphrey Building 200 Independence Ave., S.W., Room 445-G Washington, DC 20201 Re: CMS-3310-P & CMS-3311-FC, Medicare
Request for Information Regarding Accountable Care Organizations (ACOs) and Medicare Shared Savings Programs (CMS-1345-NC)
Via Electronic Submission Donald Berwick, MD, MPP Administrator Centers for Medicare & Medicaid Services ATTN: CMS-1345-NC 7500 Security Blvd. Baltimore, MD 21244-8013 Re: Request for Information Regarding
Clinical Webinar: Integrated Pharmacy
Clinical Webinar: Integrated Pharmacy Benjamin Gross, Pharm D, MBA, BCPS, BCACP, CDE, BC ADM, ASH CHC Associate Professor Director of Residency Programs Lipscomb University College of Pharmacy Objectives
Fundamentals of Medication Therapy Management (MTM) Services By Bruce R. Siecker, Ph.D., R.Ph.
Fundamentals of Medication Therapy Management (MTM) Services By Bruce R. Siecker, Ph.D., R.Ph. Bruce Siecker is president of Paradigm Research & Advisory Services, Inc. based in Stone Ridge, Virginia.
Centers for Medicare & Medicaid Services: Innovation Center New Direction
Centers for Medicare & Medicaid Services: Innovation Center New Direction I. Background One of the most important goals at CMS is fostering an affordable, accessible healthcare system that puts patients
Eligibility. Program Structure and Process for Receiving Incentives
Overview of Medicare Incentives in the Centers for Medicare & Medicaid Services (CMS) Final Rule on Meaningful Use of Certified Electronic Health Records 1 Eligibility Medicare Eligibility: For Medicare
REGULATION MARKUP REGULATION NO. 2
REGULATION MARKUP REGULATION NO. 2 The Arkansas Medical Practices Act authorizes the Arkansas State Medical Board to revoke or suspend the license issued by the Board to practice medicine if the holder
POLICY AND PROCEDURE DEPARTMENT: Pharmacy Operations
PAGE: 1 of 5 SCOPE: Centene Corporate Pharmacy Solutions, Centene Corporate Pharmacy and Therapeutics Committee, Health Plan Pharmacy Departments, Health Plan Pharmacy and Therapeutics Committees, Pharmacy
Medication Therapy Management
Medication Therapy Management Presented by Sylvia Saade, PharmD Ghada Khoury, Pharm D, BCACP Objectives Describe the components of medication therapy management (MTM) programs Discuss the needs of MTM
Describe the process for implementing an OP CDI program
1 Outpatient CDI: The Marriage of MACRA and HCCs Marion Kruse, RN, MBA Founding Partner LYM Consulting Columbus, OH Learning Objectives At the completion of this educational activity, the learner will
December 3, 2010 BY COURIER AND ELECTRONIC MAIL
Charles N. Kahn III President & CEO December 3, 2010 BY COURIER AND ELECTRONIC MAIL Donald Berwick, M.D. Administrator Centers for Medicare & Medicaid Services Attention: CMS-6028-P Hubert H. Humphrey
Measuring Value and Outcomes for Continuous Quality Improvement. Noelle Flaherty MS, MBA, RN, CCM, CPHQ 1. Jodi Cichetti, MS, RN, BS, CCM, CPHQ
Noelle Flaherty MS, MBA, RN, CCM, CPHQ 1 Jodi Cichetti, MS, RN, BS, CCM, CPHQ Leslie Beck, MS 1 Amanda Abraham MS 1 Maria Uriyo, PhD, MHSA, PMP 1 1. Johns Hopkins Healthcare LLC, Baltimore Maryland Corresponding
August 25, Dear Acting Administrator Slavitt:
August 25, 2016 Acting Administrator Andy Slavitt Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-1648-P P.O. Box 8016 Baltimore, MD 21244-8016 Re: Medicare
3. Practicing fraud, deceit, or misrepresentation in the practice of medicine.
REGULATION MARKUP REGULATION NO. 2 The Arkansas Medical Practices Act authorizes the Arkansas State Medical Board to revoke or suspend the license issued by the Board to practice medicine if the holder
Federal Legislation to Address the Opioid Crisis: Medicaid Provisions in the SUPPORT Act
October 2018 Issue Brief Federal Legislation to Address the Opioid Crisis: Medicaid Provisions in the SUPPORT Act MaryBeth Musumeci and Jennifer Tolbert On October 3, 2018, the Senate overwhelmingly passed
American Nephrology Nurses Association Comments on CMS 2015 ESRD Prospective Payment System and Quality Incentive Program
American Nephrology Nurses Association Comments on CMS 2015 ESRD Prospective Payment System and Quality Incentive Program CY 2015 ESRD PPS System Proposed Rule ANNA Comments CY 2015 ESRD PPS System Final
Leverage Information and Technology, Now and in the Future
June 25, 2018 Ms. Seema Verma Administrator Centers for Medicare & Medicaid Services US Department of Health and Human Services Baltimore, MD 21244-1850 Donald Rucker, MD National Coordinator for Health
Re: Medicare Program; Medicare Shared Savings Program: Accountable Care Organizations, Proposed rule.
June 3, 2011 Donald Berwick, MD Administrator Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS-1345-P, Mail Stop C4-26-05, 7500 Security Boulevard, Baltimore,
Subtitle E New Options for States to Provide Long-Term Services and Supports
LONG TERM CARE (SECTION-BY-SECTION ANALYSIS) (Information compiled from the Democratic Policy Committee (DPC) Report on The Patient Protection and Affordable Care Act and the Health Care and Education
June 1, President Donald J. Trump The White House 1600 Pennsylvania Avenue N.W. Washington, DC Re: Prescription Drug Importation
June 1, 2017 President Donald J. Trump The White House 1600 Pennsylvania Avenue N.W. Washington, DC 20500 Re: Prescription Drug Importation Dear President Trump: On behalf of the National Association of
PCMH 2014 Recognition Checklist
1 PCMH1: Patient Centered Access 10.00 points Element A - Patient-Centered Appointment Access ~~ MUST PASS 4.50 points 1 Providing same-day appointments for routine and urgent care (Critical Factor) Policy
Proposed amendments to the Marihuana for Medical Purposes Regulations
Proposed amendments to the Marihuana for Medical Purposes Regulations Submission in response to the Canada Gazette publication on the proposed amendments to the Marihuana for Medical Purposes Regulations
How to Participate Today 4/28/2015. HealthFusion.com 2015 HealthFusion, Inc. 1. Meaningful Use Stage 3: What the Future Holds
Meaningful Use Stage 3: What the Future Holds Dr. Seth Flam CEO, HealthFusion Presented by We ll begin momentarily Meaningful Use Stage 3: What the Future Holds Dr. Seth Flam CEO, HealthFusion Presented
The Patient-Centered Medical Home Model of Care
The Patient-Centered Medical Home Model of Care May 11, 2017 Louise Bryde Principal Presentation Outline Imperatives for Change Overview: What Is a Patient-Centered Medical Home? The Medical Neighborhood
The Pharmacist s Role in Reducing Readmissions
The Pharmacist s Role in Reducing Readmissions John Vinson, Pharm.D. UAMS West Family Medical Center Fort Smith, Arkansas Assistant Professor Co-Chair Clinical Leadership Committee UAMS Regional Programs
Improvement Activities Data Validation Criteria
Activity ID Subcategory Activity Name Activity Description Activity Validation Suggested Documentation (inclusive of dates during the selected continuous 90-day or year Name Weighting long reporting period)
Evidence-Based Practices to Optimize Prescriber Use of PDMPs
Evidence-Based Practices to Optimize Prescriber Use of PDMPs Sheri Lawal, MPH, CHES Senior Associate, Substance Use Prevention and Treatment Initiative, The Pew Charitable Trusts Thomas Clark Research
Policies Approved by the 2017 ASHP House of Delegates
House of Delegates Policies Approved by the 2017 ASHP House of Delegates 1701 Ensuring Patient Safety and Data Integrity During Cyber-attacks Source: Council on Pharmacy Management To advocate that healthcare
Objectives. Medication Therapy Management: The Important Role of the Pharmacy Technician. Medication Therapy Management (MTM)
Medication Therapy Management: The Important Role of the Pharmacy Technician Nancy Myers, PharmD, MBA, BCPS, CDE Katrina Harper, PharmD, MBA Objectives Define Medication Therapy Management () and its Core
Error! Unknown document property name.
September 10, 2018 Seema Verma, Administrator Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS-1693-P, P.O. Box 8016, Baltimore, MD 21244-8016 RE: CMS-1693-P
Evaluation of Pharmacy Delivery Models
Evaluation of Pharmacy Delivery Models As Required By House Bill 1, 84th Legislature, Regular Session, 2015 (Article II, Health and Human Services Commission, Rider 83) Health and Human Services Commission